Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus
- PMID: 30429688
- PMCID: PMC6213629
- DOI: 10.5863/1551-6776-23.5.351
Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus
Abstract
Despite pharmacotherapeutic advancements in the management of type 1 diabetes mellitus during the past several decades, patients struggle to achieve glycemic goals. Additionally, hypoglycemia, especially in extremes of age, decreases quality of life. The lack of optimal glycemic control and risk for hypoglycemia are multifactorial. Nevertheless, endeavors aiming to develop pharmacotherapeutic options with enhanced pharmacokinetic, pharmacodynamic, and clinical profiles continue. This review article discusses recent ventures in 3 categories of insulin, non-insulin, and glucagon products.
Keywords: diabetes; glucagon; insulin; non-insulin; pediatrics; type 1 diabetes mellitus.
Conflict of interest statement
Disclosures The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts and honoraria.
Similar articles
-
Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.Consult Pharm. 2014 Feb;29(2):110-23. doi: 10.4140/TCP.n.2014.110. Consult Pharm. 2014. PMID: 24513421 Review.
-
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.Am J Health Syst Pharm. 2019 Oct 15;76(21):1739-1748. doi: 10.1093/ajhp/zxz179. Am J Health Syst Pharm. 2019. PMID: 31612934 Review.
-
New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.Curr Diab Rep. 2017 Aug 18;17(10):91. doi: 10.1007/s11892-017-0926-8. Curr Diab Rep. 2017. PMID: 28822051 Review.
-
Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.Ann Pharmacother. 1998 Sep;32(9):896-905. doi: 10.1345/aph.17375. Ann Pharmacother. 1998. PMID: 9762378 Review.
-
Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.Postgrad Med. 2013 May;125(3):112-26. doi: 10.3810/pgm.2013.05.2666. Postgrad Med. 2013. PMID: 23748512 Review.
Cited by
-
Diabetic‑induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus (Review).Mol Med Rep. 2020 Aug;22(2):603-611. doi: 10.3892/mmr.2020.11175. Epub 2020 May 22. Mol Med Rep. 2020. PMID: 32468027 Free PMC article. Review.
References
-
- Cefalu WT, Bakris G, Blonde L et al. American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes. 2017;9(4):320–324. - PubMed
-
- Miller KM, Foster NC, Beck RW et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971–978. - PubMed
-
- Tresiba [package insert] Plainsboro, NJ: Novo Nordisk Inc; Dec, 2016.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous